Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL16742380 | 0.93 | CHRNA7 (0.46) | CHRNA7CNR2CA12CA1CA2 | |
| SCHEMBL18109934 | 0.75 | PLK1 (0.50) | CNR2 | |
| SCHEMBL18109931 | 0.75 | CA12 (0.42) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL18109936 | 0.73 | CA12 (0.50) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL21799295 | 0.73 | CA12 (0.47) | CA12CA1CA2CA9 | |
| Bromide SCHEMBL14742725 | 0.69 | MEN1 (0.57) | CA12CA1CA2CA9 | |
| Bromide SCHEMBL14743114 | 0.66 | MEN1 (0.64) | CA12CA1CA2CA9 | |
| SCHEMBL7068930 | 0.66 | AAK1 (0.42) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL15888157 | 0.66 | MEN1 (0.47) | CNR2CA12CA1CA2CA9 | |
| SCHEMBL28777586 | 0.66 | FFAR4 (0.50) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071582-B1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | RES & INNOVATION UK (GB) | 2020-04-29 | — | — | EP | disclosed |
| EP-3623375-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | United Kingdom Research and Innovation (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-9963474-B2 | Mitochondria-targeted dicarbonyl sequestering compounds | MEDICAL RESEARCH COUNCIL (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20160289252-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289252-A1 | MITOCHONDRIA-TARGETED DICARBONYL SEQUESTERING COMPOUNDS | NDUFAB1, HADHB, SLC25A21 | CHRNA7 4852/4885CNR2 3237/4885CA12 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.